A randomized phase 3 trial with long-term follow-up reported that adding tislelizumab to first-line chemotherapy significantly extended overall survival in advanced esophageal squamous cell carcinoma across three years. The result is notable for investors and clinicians because it extends beyond initial response endpoints into sustained survival. The study supports continued evaluation of programmed cell death axis blockade in earlier lines for esophageal cancer, where durable benefit has historically been harder to demonstrate. With follow-up now reaching the multi-year mark, the survival readout strengthens the clinical case for the combination strategy in routine treatment planning.
Get the Daily Brief